Cardiology
Acute Coronary Syndrome
| ACT | 2011, Acetylcysteine in Coronary Angiography |
| ATLAS ACS-2 | 2012, Rivaroxaban in Acute Coronary Syndrome |
| CAST I | 1991, Antiarrhythmics post-MI |
| CHAMPION PHOENIX | 2013, Cangrelor vs Clopidogrel in PCI |
| COMMIT | 2005, Metoprolol after acute MI |
| CURE | 2001, Effects of Clopidogrel plus Aspirin in Patients with NSTEMI |
| EPHESUS | 2003, Eplerenone in patients with LV dysfunction after MI |
| ESSENCE | 1997, Enoxaparin vs Unfractionated Heparin for UA/NSTEMI |
| CULPRIT-SHOCK | 2018, Culprit lesion vs multivessel PCI in ACS with cardiogenic shock |
| SCOT-HEART | 2018, CTA vs standard care in preventing MI |
| SADHART | 2002, Sertraline for depression after ACS |
| IMPROVE-IT | 2015, Ezetimibe + statin in acute coronary syndrome (ACS) |
| ULTIMATE | 2018, 2018, IVUS vs angiography-guided implantation of DES |
| FRISC II | 2006, Invasive compared with non-invasive treatment in unstable coronary artery disease |
| IABP-SHOCK II | 2012, Intraaortic Balloon Pump for Myocardial Infarction with Cardiogenic Shock |
| MADIT-II | 2002, Prophylactic Implantation of a Defibrillator in Patients with Myocardial Infarction and Reduced Ejection Fraction |
| PLATO | 2009, Ticagrelor versus clopidogrel in patients with acute coronary syndromes |
| TRITON-TIMI 38 | 2007, Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes |
| TIMACS | 2009, Early versus Delayed Invasive Intervention in Acute Coronary Syndromes |
| MIRACL | 2001, Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes |
| SMART-DATE | 2018, 6-month versus 12-month or longer DAPT after PCI in ACS |
| OAT | 2006, Coronary Intervention for Persistent Occlusion after Myocardial Infarction |
| OASIS-5 | 2006, Comparison of fondaparinux and enoxaparin in acute coronary syndromes |
Aortic Stenosis
| PARTNER A | 2011, Transcatheter versus Surgical Aortic-Valve Replacement in High-Risk Patients |
| SURTAVI | 2017, Surgical AVR or TAVR in intermediate-risk patients |
Atrial Fibrillation
| AFFIRM | 2002, Rate control vs Rhythm control in Atrial Fibrillation |
| ORBIT-AF Registry | 2013, Aspirin and OAC in Atrial Fibrillation |
| ROCKET AF | 2011, Rivaroxaban vs. warfarin in atrial fibrillation |
| ARISTOTLE | 2011, Apixaban vs. warfarin in atrial fibrillation |
| RACE II | 2010, Strict vs Lenient Control of Heart Rate in Atrial Fibrillation |
| PROTECT-AF | 2009, Percutaneous Closure of LAA in atrial fibrillation |
| CABANA | 2018, Catheter Ablation for Atrial Fibrillation |
| CASTLE-AF | 2018, Catheter Ablation for Atrial Fibrillation with Heart Failure |
| EMBRACE | 2014, Atrial fibrillation in patients with cryptogenic stroke |
Cardiac Arrest
| HACA | 2002, Hypothermia in Cardiac Arrest |
| PARAMEDIC2 | 2018, Epinephrine in Out-of-Hospital Cardiac Arrest |
| TTM | 2014, 33 vs. 36°C body temperature after cardiac arrest |
Coronary Artery Disease
| LIPID | 1998, Pravastatin in patients with coronary heart disease |
| HOPE | 2000, ACE inhibitors, ramipril in high cardiovascular risk patients |
| CHARISMA | 2006, Aspirin + clopidogrel vs. aspirin for CVD prevention |
| COURAGE | 2007, PCI for stable CAD |
| JUPITER | 2008, Rosuvastatin for prevention of CV events |
| POISE | 2008, Metoprolol succinate in patients undergoing surgery |
| SYNTAX | 2009, PCI vs CABG in severe CAD |
| DAPT | 2014, 12 or 30 months of dual antiplatelet therapy after drug-eluting stents PCI |
| COMPASS | 2017, Rivaroxaban with or without ASA in stable CAD |
| MANAGE | 2018, Dabigatran in myocardial injury after non-cardiac surgery |
| VITAL (Vitamin D) | 2018, Vitamin D3 for prevention of CVD and cancer |
| VITAL (N3) | 2018, N3 fatty acid supplements for prevention of CVD and cancer |
| REDUCE-IT | 2018, Cardiovascular risk reduction with Icosapent ethyl for hypertriglyceridemia |
| FREEDOM | 2012, Percutaneous Coronary Intervention (PCI) vs CABG in Patients with Diabetes and multivessel CAD |
| ASPREE | 2018, Aspirin for Primary Prevention in Healthy Adults |
| ARRIVE | 2018, Aspirin for Primary Prevention in Adults at Moderate Cardiovascular Risk |
| PIONEER AF-PCI | 2016, Prevention of bleeding in patients with Atrial fibrillation undergoing PCI |
| EXCEL | 2016, Everolimus-eluting stents or bypass surgery for left main coronary artery disease |
| ORBITA | 2017, Percutaneous coronary intervention in stable angina |
| CIRT | 2018, Low-dose methotrexate for the prevention of atherosclerotic events |
| EAGLES | 2018, Cardiovascular Safety of Smoking Cessation Medications |
| FOURIER | 2017, Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease |
| CANTOS | 2017, Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease |
| NORSTENT | 2016, Drug-Eluting (DES) or Bare-Metal Stents (BMS) for Coronary Artery Disease |
| DIVA | 2018, Drug-eluting stents versus bare-metal stents in saphenous vein grafts |
Peripheral Arterial Disease
| CREST | 2010, Stenting versus CEA in Carotid-Artery Stenosis |
Hypertension
| SPYRAL HTN-ON MED | 2018, Renal Denervation in Uncontrolled Hypertension |
| ALLHAT | 2002, Antihypertensive drugs to prevent Heart Attack |
| Barber Cluster Trial | 2018, Barbershop Interventions in Controlling Blood Pressure |
| Ambulatory BP and Mortality | 2018, Ambulatory BP measurements and mortality |
| SPRINT | 2015, Intensive Versus Standard Blood Pressure Control |
Heart Failure
| TOPCAT | 2014, Spironolactone in HFpEF |
| COAPT | 2018, Mitral valve repair in Patients with Heart failure |
| COMET | 2003, Comparison of Carvedilol and Metoprolol in Chronic Heart Failure |
| DIG | 1997, Digoxin in Heart failure with reduced ejection fraction |
| Ancillary DIG | 2006, Digoxin in Heart failure with preserved ejection fraction |
| SURVIVE | 2007, Levosimendan in acute decompensated heart failure |
| DOSE | 2011, Furosemide in Acute Decompensated Heart Failure |
| PIONEER-HF | 2018, Angiotensin-neprilysin inhibition in acute decompensated heart failure |
| PARADIGM-HF | 2014, Angiotensin-neprilysin inhibition versus enalapril in heart failure |
| BLOCK HF | 2013, Biventricular versus Right Ventricular Pacing in Heart Failure Patients with Atrioventricular Block |
| MITRA-FR | 2018, Percutaneous Repair or Medical Treatment for Secondary Mitral Regurgitation |
| RALES | 1999, The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure |
| CORONA | 2007, Rosuvastatin in Older Patients with Systolic Heart Failure |
Thromboembolism
| WARFASA | 2012, Aspirin for Recurrent VTE |
| EINSTEIN-PE | 2012, Rivaroxaban for Acute PE |
| AMPLIFY | 2013, Apixaban for VTE |
| ANNEXA | 2015, Andexanet for reversal of Factor Xa Inhibitors |
| ADJUST PE | 2014, Age Adjusted D Dimer for PE |
| MOPETT | 2013, Low-dose tPA for submassive PE |
| SOME | 2015, Cancer screening in unprovoked VTE |
| AVERT | 2018, Apixaban to Prevent Venous Thromboembolism (VTE) in Patients with Cancer |
Stroke
| SPARCL | 2006, High-dose atorvastatin after stroke or transient ischemic attack (TIA) |
| SOCRATES | 2016, Ticagrelor versus aspirin in acute stroke or TIA |
| EXTEND-IA TNK | 2018, Tenecteplase vs Alteplase in Ischemic Stroke |
| WAKE-UP | 2018, MRI guided thrombolysis with alteplase in stroke with unknown time of onset |
| DEFUSE-3 | 2018, Thrombectomy for Stroke at 6 to 16 Hours with Selection by Perfusion Imaging |
| RESPECT | 2013, Closure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic Stroke |
| Gore REDUCE | 2017, Patent Foramen Ovale Closure or Antiplatelet Therapy for Cryptogenic Stroke |
| CLOSURE I | 2012, Closure or Medical Therapy for Cryptogenic Stroke with Patent Foramen Ovale |
Ventricular Tachycardia
| VANISH | 2016, Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs |
Infectious Disease
HIV
| INSIGHT START | 2015, INSIGHT START: Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection |
Infections
| Fidaxomicin in C. diff Infection | 2011, Fidaxomicin versus vancomycin for Clostridium difficile infection |
| PRORATA | 2010, Procalcitonin guided antibiotic therapy in critically ill patients |
| PROACT | 2018, Procalcitonin in Lower Respiratory Tract Infections |
| POET | 2018, IV vs PO Antibiotics in Infective Endocarditis |
| MERINO | 2018, Piperacillin-Tazobactam vs Meropenem in Ceftriaxone resistant Infections |
| CAPSTONE-1 | 2018, Baloxavir Marboxil for Uncomplicated Influenza |
| STOP-IT | 2015, Short-Course Antimicrobial Therapy for Intraabdominal Infection |
Hepatitis C
| DAHHS2 | 2019, Treatment of acute hepatitis C with 8 weeks of grazoprevir plus elbasvir |
| VALENCE | 2014, Sofosbuvir and ribavirin in HCV |
Sepsis
| PROWESS-SHOCK | 2012, Activated protein C (DrotAA) in Sepsis |
| TRISS | 2014, Restrictive vs Liberal Transfusion in Septic Shock |
| ALBIOS | 2014, Albumin in Severe Sepsis and Septic Shock |
| SALT-ED | 2018, Balanced crystalloids versus saline in non-critically ill adults |
| ADRENAL | 2018, Glucocorticoids in Septic Shock |
| APROCCHSS | 2018, Hydrocortisone + Fludrocortisone in Septic Shock |
| BICAR-ICU | 2018, Sodium Bicarbonate in Severe Metabolic Acidaemia |
Nephrology
Nephropathy
| IDNT | 2001, Irbesartan in diabetic nephropathy |
| RENAAL | 2012, Losartan in diabetic nephropathy |
Dialysis
| IDEAL | 2010, Early versus Late Dialysis in Patients with ESRD |
| AKIKI | 2016, Renal Replacement Therapy in ICU |
| RENAL | 2009, Intensity of Continuous Renal-Replacement Therapy in Critically Ill Patients |
Endocrinology
Diabetes
| EMPA-REG OUTCOMES | 2015, Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes |
| CANVAS | 2017, Canagliflozin in Type II DM |
| ASCEND ASA | 2018, Aspirin for primary prevention of CVD in DM |
| ASCEND N3 | 2018, N3 fatty acid supplements for primary prevention in DM |
| RABBIT2 | 2007, Basal-bolus insulin in inpatients with DM |
| Metformin in CKD Cohort | 2018, Metformin in CKD |
| Closed Loop Insulin Trial | 2018, Closed-loop Insulin Delivery in Non-ICU patients |
| ACCORD | 2008, Effects of Intensive Glucose Lowering in Type 2 Diabetes |
| LEADER | 2016, Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes |
Gastroenterology
GI bleed
| SUP-ICU | 2018, Pantoprazole in Patients at Risk for Gastrointestinal Bleeding in the ICU |
| POP-UP | 2016, Pantoprazole or Placebo for Stress Ulcer Prophylaxis |
Cirrhosis
| Albumin in SBP | 1999, IV albumin in patients with cirrhosis and SBP |
| Rifaxamin in HE | 2013, Rifaxamin in hepatic encephalopathy |
| STOPAH | 2015, Prednisolone in Alcoholic Hepatitis |
| Bezafibrate Trial | 2018, Bezafibrate in Primary Biliary Cholangitis |
Pulmonology / Critical Care
Asthma
| EXTRA | 2011, Omalizumab in Severe Allergic Asthma |
COPD
| FLAME | 2016, LABA + LAMA vs LABA + ICS for COPD |
| REDUCE | 2013, Short term steroids in COPD exacerbation |
ARDS
| PROSEVA | 2013, Prone Positioning in Severe Acute Respiratory Distress Syndrome (ARDS) |
| ART | 2017, Lung Recruitment and Titrated PEEP vs Low PEEP in ARDS |
Mechanical Ventilation
| PReVENT | 2018, Low vs Intermediate Tidal Volume Strategy in ICU Patients Without ARDS |
Shock
| ATHOS-3 | 2017, Angiotensin II for the Treatment of Vasodilatory Shock |
| CRISTAL | 2013, Effects of fluid resuscitation with colloids vs. crystalloids on mortality in hypovolemic shock |
Trauma
| PAMPer | 2018, Prehospital Plasma in Trauma Patients |
| PROPPR | 2015, Transfusion of Plasma, Platelets, and Red Blood Cells in Severe Trauma |
Hematology / Oncology
Cancer
| COLONPREV | 2012, FIT vs. colonoscopy for colon cancer screening |
| NELSON | 2018, CT scan for screening lung cancer |
| AGE | 2006, Mammographic screening from age 40 years |
| Metachronous Gastric Trial | 2018, H-Pylori treatment in Metachronous Gastric Cancer |
| PACIFIC | 2018, Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC |
| FREGAT | 2019, Hybrid Minimally Invasive Esophagectomy for Esophageal Cancer |
Anemia
| CHOIR | 2006, Erythropoetin for anemia in non-dialysis CKD |
Arthritis
| METEOR | 2013, Surgery vs Physical Therapy for a Meniscal Tear and Osteoarthritis |
| BeSt | 2005, DMARD with prednisone or infliximab in RA |
| LESS | 2014, Epidural Glucocorticoid Injections for Spinal Stenosis |